Skip to main content

Table 1 14-3-3σ immunostaining in relation to clinicopathological variables

From: The clinicopathological and prognostic impact of 14-3-3 sigma expression on vulvar squamous cell carcinomas

Variables Total Cytoplasm Nucleus Cytoplasm and nucleus
  n Low High (%) p 1 Low High (%) p 1 Low High (%) p 1
Age      0.21     0.96     0.06
   25–69 121 39 82 (68)   49 72 (60)   38 83 (69)  
   70–84 147 34 113 (77)   62 85 (58)   28 119 (81)  
   85+ 34 11 23 (68)   14 20 (59)   10 24 (71)  
FIGO      0.26     0.49     0.08
   Ia 11 2 9 (82)   4 7 (64)   2 9 (82)  
   Ib 37 16 21 (57)   19 18 (49)   16 21 (57)  
   II 110 28 82 (75)   43 67 (61)   22 88 (80)  
   III 121 32 89 (74)   46 75 (62)   30 91 (75)  
   IV 19 5 14 (74)   10 9 (47)   5 14 (74)  
   Not available 4             
Lymph node metastasis      0.42     0.97     0.54
   None 137 41 96 (70)   55 82 (60)   36 101 (74)  
   Unilateral 76 18 58 (76)   31 45 (59)   17 59 (78)  
   Bilateral 34 12 22 (65)   13 21 (62)   11 23 (68)  
   Not available 55             
Tumour diameter (cm)      0.001     0.002     0.001
   0.3–2.5 92 34 58 (63)   50 42 (46)   33 59 (64)  
   2.6–4.0 94 30 64 (68)   35 59 (63)   25 69 (73)  
   4.1–20.0 100 14 86 (86)   30 70 (70)   12 88 (88)  
   Not available 16             
Tumor differentiation      0.09     0.10     0.08
   Well 76 27 49 (65)   39 37 (49)   25 51 (67)  
   Moderate 154 43 111 (72)   61 93 (60)   39 115 (75)  
   Poor 72 14 58 (81)   25 47 (65)   12 60 (83)  
Depth of invasion (mm)      0.01     0.001     0.007
   0.0–4.0 80 32 48 (60)   45 35 (44)   30 50 (63)  
   4.1–8.0 99 24 75 (76)   38 61 (62)   21 78 (79)  
   8.1–40.0 112 24 88 (79)   34 78 (70)   21 91 (81)  
   Not available 11             
Infiltration of vessel      0.33     0.50     0.41
   No 233 67 166 (71)   99 134 (58)   61 172 (74)  
   Yes 66 15 51 (77)   25 41 (62)   14 52 (79)  
   Not available 3             
p142      1.00     1.00     0.88
   Low (-) 135 98 37 (27)   46 89 (66)   84 51 (38)  
   High (+) 77 56 21 (27)   26 51 (66)   49 28 (36)  
   Not available 100             
p162      0.63     0.88     0.15
   Low (< 5%) 148 40 108 (73)   51 97 (66)   37 111 (75)  
   High (≥ 5%) 63 15 48 (76)   21 42 (67)   10 53 (84)  
   Not available 91             
p212      0.17     0.87     0.10
   Low (-) 122 36 86 (71)   42 80 (66)   32 90 (74)  
   High (+) 90 19 71 (79)   30 60 (67)   15 75 (84)  
   Not available 90             
p272      0.18     0.56     0.19
   Low (< 50%) 164 39 125 (76)   54 110 (67)   33 131 (80)  
   High (≥ 50%) 48 16 32 (67)   18 30 (63)   14 34 (71)  
   Not available 90             
p532      0.70     0.12     0.93
   Low (< 5%) 93 25 68 (73)   26 67 (72)   20 73 (79)  
   High (≥ 5%) 118 29 89 (75)   45 73 (62)   26 92 (78)  
   Not available 91             
Cyclin A2      0.68     0.09     0.59
   Low (< 5%) 61 17 44 (72)   26 35 (57)   15 46 (75)  
   High (≥ 5%) 151 38 113 (75)   46 105 (70)   32 119 (79)  
   Not available 90             
Cyclin D12      0.87     0.75     0.83
   Low (-) 156 40 116 (74)   52 104 (67)   34 122 (78)  
   High (+) 56 15 41 (73)   20 36 (64)   13 43 (77)  
   Not available 90             
Cyclin D32      0.25     0.76     0.69
   Low (< 50%) 153 43 110 (72)   51 102 (67)   35 118 (77)  
   High (≥ 50%) 59 12 47 (80)   21 38 (64)   12 47 (80)  
   Not available 90             
Cyclin E2      0.72     0.64     0.32
   Low (< 50%) 173 44 129 (75)   60 113 (65)   36 137 (79)  
   High (≥ 50%) 39 11 28 (72)   12 27 (69)   11 28 (72)  
   Not available 90             
HPV2      0.87     0.47     0.98
   Low (-) 168 44 124 (74)   57 111 (66)   39 129 (77)  
   High (+) 44 11 33 (75)   15 29 (66)   8 36 (82)  
   Not available 90             
  1. 1 Pearson chi-square 2 In previous reports, p53, p16, p21, p27, p14, cyclin A, cyclin D1, cyclin D3, cyclin E and HPV have been studied [28–31].
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us